Cara Therapeutics (CARA): 3Q Looks Fine But 2017 Catalysts Are Key - HC Wainwright

November 7, 2016 7:47 AM EST
Get Alerts CARA Hot Sheet
Price: $11.43 -1.47%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CARA Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

H.C. Wainwright analyst, Corey Davis, reiterated his Buy rating on shares of Cara Therapeutics (NASDAQ: CARA) noting 3 key potential catalysts in 1H17.

The upcoming catalysts include: 1) Phase 2/3 with IV '845 in pruritis; 2) Phase 3 with IV '845 in post-op pain; and 3) Phase 2 with oral '845 in osteoarthritis. The analyst stated "If we're correct, and all three are positive, we feel this would be a major inflection point for the stock".

For an analyst ratings summary and ratings history on Cara Therapeutics click here. For more ratings news on Cara Therapeutics click here.

Shares of Cara Therapeutics closed at $7.27 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

H.C. Wainwright

Add Your Comment